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INTRODUCTION
Epidemiologic evidence has shown
that chronic activation of intracellular
proinflammatory pathways related to
obesity can lead to the development of
insulin resistance and cardiovascular
diseases (1). In this sense, the inflamma-
tory protein calprotectin was recently
described as a novel marker of obesity,
with its circulating levels being in-
creased not only in obese subjects but
also in type 1 diabetic patients (2,3). Cal-
protectin is a heterodimer comprising
the S100A8 (calgranulin A, MRP8) and
S100A9 (calgranulin B, MRP14) subunits,
which are low-molecular-weight mem-
bers of a subfamily of S100 calcium-
binding proteins called calgranulins (4).
The S100A8/A9 complex is expressed in
a  tissue/cell-specific manner mainly in
cells of the myeloid lineage, including
monocytes, neutrophils and early-
 differentiation states of macrophages (5).
However, the S100A8/A9 expression is
also inducible in mature macrophages,
osteoclasts, keratinocytes, fibroblasts
and microvascular endothelial cells (6).
Besides extracellular functions related to
antiinfectious host defense mechanisms,
calprotectin is also involved in the regu-
lation of kinase activities, cytoskeletal
 rearrangement, differentiation and cell
migration, with recent attention being
focused on the involvement of
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Calprotectin has been recently described as a novel marker of obesity. The aim of this study was to determine the circulating
concentrations and expression levels of calprotectin subunits (S100A8 and S100A9) in visceral adipose tissue (VAT), exploring its im-
pact on insulin resistance and inflammation and the effect of weight loss. We included 53 subjects in the study. Gene expression
levels of the S100A8/A9 complex were analyzed in VAT as well as in both adipocytes and stromovascular fraction cells (SVFCs). In
addition, circulating calprotectin and soluble receptor for the advanced glycation end product (sRAGE) concentrations were
measured before and after weight loss achieved by Roux-en-Y gastric bypass (RYGB) (n = 26). Circulating concentrations and VAT
expression of S100A8/A9 complex were increased in normoglycemic and type 2 diabetic obese patients (P < 0.01) and associated
with markers of inflammation (P < 0.01). Oppositely, concentrations of sRAGE were significantly lower (P < 0.001) in both obese
groups compared to lean volunteers. Elevated calprotectin levels in obese patients decreased (P < 0.00001) after RYGB, whereas
sRAGE concentrations tended to increase. Calprotectin was mainly expressed by SVFCs, and its expression was significantly corre-
lated (P < 0.01) with mRNA levels of the monocyte-macrophage–related molecules macrophage-specific antigen CD68 (CD68),
monocyte chemotactic protein 1 (MCP1), integrin α-M (CD11B), and NADPH oxidase 2 (NOX2). Tumor necrosis factor-α treatment
significantly enhanced (P < 0.05) the mRNA levels of S100 calcium-binding protein A8 (S100A8) of human visceral adipocytes. The
increased levels of calprotectin in obesity and obesity-associated type 2 diabetes, its positive association with inflammation as well
as the higher expression levels in the SVFCs in VAT suggests a potential role of this protein as a chemotactic factor in the recruit-
ment of macrophages to VAT, increasing inflammation and the development of obesity-associated comorbidities.
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S100A8/A9 in cancer (6,7). In line with
these functions, phagocytes reportedly
express S100A8 and S100A9 under mul-
tiple inflammatory conditions, i.e., in-
flammatory bowel disease, rheumatoid
arthritis or allograft rejection (8–10),
whereas numerous pathological condi-
tions associated with inflammation in
humans are associated with elevated
S100A8 and S100A9 levels (11). Further-
more, the inflammatory factors inter-
leukin (IL)-1, interferon (IFN)-γ and
tumor necrosis factor (TNF)-α induce
the expression and secretion of the
S100A8/A9 heterodimer (12–14). It has
been shown that the release of
S100A8/A9 from monocytes during the
inflammatory stimulation takes place via
an energy-dependent pathway involving
protein kinase C activation (12). Circu-
lating calprotectin may be involved in
inflammation by enhancing CD11b ex-
pression in human monocytes and by
participating in the transendothelial mi-
gration mechanism, thereby contributing
to an accumulation of monocytes at the
site of inflammation (15). During the
progression of inflammation, due to the
generation of reactive oxygen species
and the synthesis of nitric oxide, irre-
versible oxidative modifications of
S100A8/A9 may affect its functions (16).
S100A8/A9 also serves as a regulator for
NADPH oxidase (NOX) and may facili-
tate its activation to increase reactive
oxygen species generation. The hetero-
complex S100A8/A9 also interacts with
heparin and heparan sulfate gly-
cosaminoglycans, the receptor for the
advanced glycation end product
(RAGE), the scavenger receptor CD36
and the toll-like receptor 4 (17). More-
over, by sequestration of zinc, calpro-
tectin is able to regulate many important
processes in the body. It has been de-
scribed that calprotectin inhibits matrix
metalloproteinases, zinc-dependent en-
zymes that are important in angiogene-
sis and inflammation (7).
Visceral adipose tissue (VAT) is an im-
portant initiator of the inflammatory re-
sponse in obesity because of its ability
to produce and secrete a variety of pro-
teins involved in the development of
obesity-related derangements (18). Be-
cause calprotectin has emerged as an
important mediator of chronic inflam-
mation (19), the aim of the present
study was to determine gene expression
levels of the S100A8/A9 complex in
VAT together with circulating concen-
trations in healthy control subjects,
obese normoglycemic (NG) individuals
and obese patients with type 2 diabetes
(T2D). To gain insight the molecular
links, the relation of calprotectin with
key genes and circulating proteins in-
volved in inflammation as well as the
effect of TNF-α in human adipocyte cul-
ture was further explored. To corrobo-
rate the functional relation between obe-
sity and inflammation, the present study
also analyzed the effect on plasma cal-
protectin concentrations of Roux-en-Y
gastric bypass (RYGB), an intervention
with proven weight loss and antiinflam-
matory effects.
MATERIALS AND METHODS
Patient Selection
To analyze the effect of obesity and
T2D on the concentrations of calpro-
tectin, 53 females were recruited from
healthy volunteers and patients attend-
ing the Departments of Endocrinology
and Surgery at the Clínica Universidad
de Navarra. Patients underwent a clini-
cal assessment including medical his-
tory, physical examination, body com-
position analysis and comorbidity
evaluation by a multidisciplinary con-
sultation team. Body mass index (BMI)
was calculated as weight in kilograms
divided by the square of height in me-
ters, and body fat (BF) was estimated by
air-displacement plethysmography
(Bod-Pod®; Life Measurements, Con-
cord, CA, USA) (20). Waist-to-hip ratio
(WHR) was measured as the quotient
between the circumference of the waist
(at the midway level between the mar-
gin of the lowest rib and the iliac crest)
and the hip (at the widest trochanters).
Obese patients were further subclassi-
fied according to the established diag-
nostic thresholds for diabetes (NG: fast-
ing plasma glucose concentration <100
mg/dL and plasma glucose <140
mg/dL 2 h after an oral glucose toler-
ance test [OGTT]; T2D: fasting plasma
glucose >126 mg/dL or plasma glucose
≥200 mg/dL 2 h after OGTT) (21). T2D
subjects were not on insulin therapy or
on medications likely to influence en-
dogenous insulin levels. Furthermore,
gene expression levels were assessed in
VAT in a subgroup of subjects (n = 29).
The samples were collected from pa-
tients undergoing either Nissen fundo-
plication (for hiatus hernia repair in
lean [LN] volunteers) or RYGB (for mor-
bid obesity treatment in obese subjects)
at the Clínica Universidad de Navarra.
Both interventions were carried out via
a laparoscopic approach. Tissue samples
were immediately frozen in liquid nitro-
gen and stored at –80ºC for subsequent
analyses. In addition, a group of 26
obese female patients was selected to in-
vestigate the effect of weight loss
achieved by RYGB (after a mean of 13
months) on circulating concentrations of
calprotectin. The study was approved,
from an ethical and scientific stand-
point, by the hospital’s ethical commit-
tee responsible for research, and written
informed consent of participants was
obtained.
Blood Assays
Plasma samples were obtained by
venipuncture after an overnight fast.
Glucose was analyzed on the basis of en-
zymatic spectrophotometric reactions by
an automated analyzer (Hitachi Modular
P800; Roche, Basel, Switzerland). Insulin
was measured by means of an enzyme-
amplified chemiluminescence assay
 (IMMULITE®; Diagnostic Products, Los
Angeles, CA, USA) with intra- and in-
terassay coefficients of variation of 4.2%
and 5.7%, respectively. Insulin resistance
and sensitivity were calculated using the
homeostatic model assessment (HOMA)
and quantitative insulin sensitivity
check index (QUICKI) indices, respec-
tively (22,23). Total cholesterol, high-
density lipoprotein (HDL) cholesterol
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and low-density lipoprotein (LDL) cho-
lesterol  levels were calculated as previ-
ously described (23). Uric acid, alanine
aminotransferase, aspartate aminotrans-
ferase, alkaline phosphatase, γ-glutamyl-
transferase and creatinine were mea-
sured by enzymatic tests (Roche) in an
automated analyzer (Roche/Hitachi
Modular P800). High-sensitivity 
C-reactive protein (CRP), fibrinogen and
von Willebrand factor (vWF) antigen
concentrations were determined as pre-
viously reported (23). Leptin was mea-
sured by a double-antibody radioim-
munoassay method (Linco Research, St.
Charles, MO, USA); intra- and interassay
coefficients of variation were 5.0% and
4.5%, respectively. Adiponectin was de-
termined using a commercially available
enzyme-linked immunosorbent assay kit
(Biovendor, Heidelberg, Germany), with
the intra- and interassay coefficients of
variation being 6.7% and 7.8%, respec-
tively. Calprotectin and the soluble
RAGE (sRAGE) levels were assessed
using commercially available enzyme-
linked immunosorbent assay kits (R&D
Systems Europe, Abingdon, U.K.) ac-
cording to the manufacturer’s instruc-
tions. The intra- and interassay coeffi-
cients of variation were 3.7% and 6.5%,
respectively, for the former and 5.7%
and 7.7% for the latter.
Multiplex Immunoassays
The circulating concentrations of dif-
ferent inflammatory markers were quan-
tified with a Luminex™ 200 platform
(Luminex, Austin, TX, USA) using
 microsphere-based multiplexing technol-
ogy. The human immunoassay kit (Milli-
pore Iberica, Madrid, Spain), encompass-
ing analyte-specific components for the
measurement of E-selectin, intercellular
adhesion molecule 1 (ICAM-1), IL-6,
plasminogen activator inhibitor-1 (PAI-
1), vascular cell adhesion protein-1 and
TNF-α, was used in the study. The stan-
dard curve was calculated using five-
 parameter-curve fitting, and results were
analyzed using the Luminex IS™ 2.3
software (Luminex). Intraassay precision
ranged from 4.5% to 12.3%, whereas in-
terassay precision was <16.3%. Calibra-
tors, controls and samples were run in
duplicate throughout the study.
RNA Extraction and Real-Time
Polymerase Chain Reaction
Adipose tissue RNA isolation was per-
formed by homogenization with an
ULTRA-TURRAX® T 25 basic (IKA
Werke, Staufen, Germany) using QIAzol®
Reagent (Qiagen, Valencia, CA, USA).
Samples were purified with the RNeasy
Lipid Tissue Mini-Kit (Qiagen) according
to the manufacturer’s directions and
treated with DNase I (RNase-free DNase
Set; Qiagen) to remove any trace of ge-
nomic DNA. For first-strand cDNA syn-
thesis, constant amounts of 1 μg total
RNA were reverse-transcribed in a 40-μL
final volume using random hexamers
(Roche) as primers and 200 units
Moloney murine leukemia virus (M-MLV)
reverse transcriptase (Invitrogen, Carls-
bad, CA, USA) (24).
The transcript levels for S100 calcium-
binding protein A8 (S100A8), S100 calcium-
binding protein A9 (S100A9), integrin α-M
(CD11B), macrophage-specific antigen CD68
(CD68), monocyte chemotactic protein 1
(MCP1), NADPH oxidase 2 (NOX2) and
tumor necrosis factor-α (TNFA) were quan-
tified by real-time polymerase chain reac-
tion (PCR) (7300 Real Time PCR System;
Applied Biosystems, Foster City, CA,
USA). Primers and probes (Supplemen-
tary Table 1) were designed using the
software Primer Express 2.0 (Applied
Biosystems) and purchased from Genosys
(Sigma-Aldrich, Madrid, Spain). Primers
or TaqMan® probes encompassing frag-
ments of the areas from the extremes of
two exons were designed to ensure the
detection of the corresponding transcript
avoiding genomic DNA amplification.
The cDNA was amplified at the following
conditions: 95°C for 10 min, followed by
45 cycles of 15 s at 95°C and 1 min at
59°C, using the TaqMan® Universal PCR
Master Mix (Applied Biosystems). The
primer and probe concentrations for gene
amplification were 300 and 200 nmol/L,
respectively. All results were normalized
to the levels of the ribosomal 18S rRNA
(Applied Biosystems), and relative quan-
tification was calculated using the ΔΔCt
formula (Ct, cycle threshold) (25). Relative
mRNA expression was expressed as fold
expression over the calibrator sample (av-
erage of gene expression corresponding to
the LN group), as previously described.
All samples were run in triplicate, and the
average values were calculated (25).
Adipocyte Culture
Human stromovascular fraction cells
(SVFCs) were isolated from omental adi-
pose tissue from obese normoglycemic
subjects as previously described (26).
SVFCs were seeded at 2 × 105 cell/cm2
and grown in adipocyte medium
(DMEM/F-12 [1:1] [Invitrogen],
17.5 mmol/L glucose, 16 μmol/L biotin,
18 μmol/L panthotenate, 100 μmol/L
ascorbate and antibiotic-antimycotic)
supplemented with 10% newborn calf
serum. After 4 d, the medium was
changed to adipocyte medium supple-
mented with 3% newborn calf serum,
0.5 mmol/L 3-isobutyl-1-methylxanthine
(IBMX), 0.1 μmol/L dexamethasone,
1 μmol/L BRL49653 and 10 μg/mL in-
sulin. After a 3-d induction period, cells
were fed every 2 d with the same me-
dium but without IBMX and BRL49653
supplementation for the remaining 7 d of
adipocyte differentiation.
Differentiated human omental
adipocytes were serum-starved for 24 h
and then treated with increasing concen-
trations of TNF-α (1, 10 and 100 ng/mL)
(Sigma) for 24 h.
Statistical Analysis
Data are presented as mean ± stan-
dard error of the mean (SEM). Because
of their nonnormal distribution, CRP
concentrations were logarithmically
transformed. The normal distribution of
the other variables was adequate for the
use of parametric tests. Differences be-
tween groups were assessed by one-way
ANOVA followed by Tukey post hoc
tests and two-tailed paired t tests as ap-
propriate. Differences between groups
adjusted for age were analyzed by anal-
ysis of covariance (ANCOVA). Pearson
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correlation coefficients (r) were used to
analyze the association between vari-
ables. The calculations were performed
using the SPSS/Windows version 15.0
statistical package (SPSS, Chicago, IL,
USA). A P value <0.05 was considered
statistically significant.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Increased Circulating Calprotectin
Levels in Human Obesity and Obesity-
Associated T2D Decrease After Weight
Loss
The biochemical and hormonal charac-
teristics of the subjects included in the
study are shown in Table 1. Patients from
both obese groups were anthropometri-
cally similar between them exhibiting sig-
nificantly higher (P < 0.01) BMI, BF, waist
circumference and WHR compared to the
LN volunteers. As expected, the high BF
values were accompanied by hypoad-
iponectinemia (P < 0.05) and hyper-
leptinemia (P < 0.01) together with re-
duced circulating concentrations of HDL
cholesterol (P < 0.05). Obese patients with
T2D exhibited a lower insulin sensitivity
than both LN and obese NG individuals,
as evidenced by the increased glucose
concentrations in the fasting state (P <
0.01) and 2 h after an OGTT (P < 0.01) as
well as the higher HOMA (P < 0.01) and
lower QUICKI (P < 0.01) indices.
Significant differences in circulating
calprotectin concentrations between the
three experimental groups were ob-
served (P < 0.001), being significantly
increased in both obese groups com-
pared to LN subjects (Figure 1A). Be-
cause the obese T2D group was signifi-
cantly older, an ANCOVA with age as a
covariable was performed to investigate
the effect of age on plasma calprotectin
levels. We observed similar results, with
calprotectin levels being significantly in-
creased (P < 0.001) in both obese NG
and T2D patients compared to LN sub-
jects. In this regard, plasma calprotectin
levels were positively associated (P <
0.05) with BMI, BF, waist circumference
and WHR as well as with leptin and
fasting insulin concentrations, while
being negatively correlated with the
QUICKI index (Table 2). Because calpro-
tectin constitutes a ligand of sRAGE, the
circulating concentrations of sRAGE
were also measured. We found that con-
centrations of sRAGE were significantly
lower (P < 0.001) in both obese groups
compared to LN volunteers (Figure 1B).
These differences were maintained (P <
0.001) after age adjustment. Noteworthy,
a statistically significant inverse correla-
tion between circulating levels of
sRAGE and calprotectin (r = –0.35; P =
0.013) was found. Moreover, sRAGE
concentrations were negatively corre-
lated (P < 0.01) with BMI, BF, waist cir-
cumference and WHR as well as with
leptin and fasting glucose and insulin
concentrations. A positive association
(P < 0.0001) was found between sRAGE
and the QUICKI index (Table 2).
Once the association between calpro-
tectin and its receptor with variables in-
dicative of obesity and inflammation
was established, we further analyzed
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Table 1. Anthropometric and biochemical characteristics of subjects included in the study.
Lean Obese NG Obese T2D
n 16 20 17
Age (years) 32 ± 5 34 ± 2 49 ± 3a
BMI (kg/m2) 20.4 ± 0.8 44.0 ± 1.3b 47.0 ± 2.4b
Body fat (%) 26.2 ± 2.0 53.8 ± 0.9b 54.1 ± 1.2b
Waist circumference (cm) 66.8 ± 1.3 112.8 ± 3.6b 130.6 ± 4.7b,c
WHR 0.76 ± 0.03 0.86 ± 0.02a 0.90 ± 0.02b
Fasting glucose (mg/dL) 88.8 ± 5.8 90.7 ± 3.2 131.2 ± 12.9b,d
2-h OGTT glucose (mg/dL) 101.0 ± 14.1 120.0 ± 8.4 238.1 ± 37.5b,d
Fasting insulin (μU/mL) 7.2 ± 1.4 12.8 ± 1.7 28.5 ± 4.1b,d
2-h OGTT insulin (μU/mL) 8.5 ± 1.9 87.5 ± 13.9 132.6 ± 33.5b,d
HOMA 1.7 ± 1.0 2.9 ± 0.4 9.8 ± 2.4b,d
QUICKI 0.367 ± 0.043 0.333 ± 0.006b 0.288 ± 0.008b,d
Triglycerides (mg/dL) 76 ± 13 98 ± 8 130 ± 14a
Cholesterol (mg/dL) 182 ± 11 194 ± 10 202 ± 11
LDL cholesterol (mg/dL) 102 ± 11 130 ± 9 129 ± 12
HDL cholesterol (mg/dL) 61 ± 4 44 ± 2b 48 ± 5a
Leptin (ng/mL) 8.3 ± 1.6 64.7 ± 7.0b 67.3 ± 7.0b
Adiponectin (μg/mL) 21.4 ± 5.4 8.1 ± 1.2a 10.0 ± 0.6a
Uric acid (mg/dL) 4.0 ± 0.2 5.1 ± 0.3 5.9 ± 0.4b
CRP (mg/L) 1.1 ±  0.3 8.4 ± 1.3b 13.3 ± 3.9b
Fibrinogen (mg/dL) 208 ± 24 363 ± 27b 385 ± 25b
vWF (%) 65 ± 10 97 ± 12 125 ± 17a
Homocysteine (μmol/L) 6.8 ± 0.9 6.8 ± 0.5 8.3 ± 0.6
IL-6 (pg/mL) 1.6 ± 0.1 2.5 ± 0.2b 2.8 ± 0.3b
TNF-α (pg/mL) 2.05 ± 0.06 2.40 ± 0.16 2.67 ± 0.13b
PAI-1 (ng/mL) 0.10 ± 0.01 0.22 ± 0.02b 0.50 ± 0.08b,d
E-selectin (ng/mL) 0.11 ± 0.01 0.17 ± 0.02 0.28 ± 0.04b,c
ICAM-1 (ng/mL) 0.75 ± 0.05 0.81 ± 0.06 0.81 ± 0.6
Vascular cell adhesion protein-1 (ng/mL) 5.73 ± 0.61 5.22 ± 0.26 7.12 ± 0.52c
Alanine aminotransferase (UI/L) 7 ± 1 20 ± 3 33 ± 6b,c
Aspartate aminotransferase (UI/L) 11 ± 1 13 ± 1 21 ± 5
Alkaline phosphatase (UI/L) 88 ± 9 109 ± 8 122 ± 10
γ-Glutamyltransferase (UI/L) 9 ± 1 18 ± 2 33 ± 6b,c
Data are mean ± SEM. Differences between groups were analyzed by one-way ANOVA
followed by Tukey post hoc tests.
aP < 0.05 and bP < 0.01 versus LN.
cP < 0.05 and dP < 0.01 versus obese NG. CRP was logarithmically transformed for statistical
analysis because of its nonnormal distribution.
the functional relation between them in
an intervention with proven weight loss
and insulin-sensitizing effects as well as
known for ameliorating the low-grade
chronic inflammation such as the
RYGB. After an average postsurgical
period of 13 months from the RYGB,
patients experienced a significant de-
crease (P < 0.0001) in body weight, BMI,
BF and waist circumference as well as a
significant improvement in the
presurgery glycemia (P = 0.006), insu-
linemia (P = 0.047), HOMA (P = 0.007)
and QUICKI (P < 0.0001) indices (Sup-
plementary Table 2). Of note, our data
show that weight loss after RYGB was
accompanied by a statistically signifi-
cant reduction (P < 0.01) in the circulat-
ing concentrations of calprotectin in
both NG and T2D obese patients (Fig-
ure 1C). The improvement in weight
control achieved by bariatric surgery
also resulted in a modest increase of
sRAGE levels in both obese groups, al-
though the differences fell out of statis-
tical significance (Figure 1D). Interest-
ingly, the differences in calprotectin
concentrations were positively corre-
lated with the differences in the WHR 
(r = 0.88; P = 0.004) as well as with the
differences in the concentrations of the
inflammatory markers CRP (r = 0.93; 
P = 0.044) and von Willebrand factor 
(r = 0.98; P = 0.038).
Calprotectin Gene Expression Levels
in VAT Are Increased in Obesity and
Obesity-Associated T2D
To gain more insight into the molecu-
lar mechanism involved in the increased
circulating calprotectin concentrations
observed in obese individuals, we fur-
ther explored in VAT the gene expression
levels of calprotectin in these pathophys-
iological conditions. Real-time PCR anal-
ysis indicated that S100A8 mRNA ex-
pression levels in VAT were significantly
higher in obese patients with T2D than
in both LN (P < 0.001) and obese NG vol-
unteers (P = 0.003) (Figure 2A). S100A9
mRNA expression in VAT followed a
similar trend, being significantly in-
creased in obese T2D patients (P = 0.037)
compared to the LN group, but no statis-
tically significant differences were de-
tected compared to the obese NG sub-
jects (Figure 2B). A positive correlation
between S100A8 and S100A9 gene ex-
pression in VAT was found (r = 0.60; P <
0.001). However, no significant correla-
tion of circulating calprotectin with ei-
ther S100A8 mRNA (P=0.220) or S100A9
mRNA (P = 0.166) expression levels in
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Figure 1. Circulating levels of calprotectin and sRAGE of LN, obese NG and obese T2D vol-
unteers as well as the effect of weight loss in obese patients achieved by RYGB. Bars rep-
resent the mean ± SEM of calprotectin and sRAGE plasma concentrations under basal
conditions (LN: n = 16; NG: n = 20; T2D: n = 17) (A, B) and 13 months after RYGB (n = 26)
(C, D). Differences between groups were analyzed by one-way ANOVA followed by Tukey
tests or by two-tailed paired Student t tests. **P < 0.01 versus LN and versus presurgery
 values.
Table 2. Univariate analysis of the correlations between circulating concentrations of
calprotectin and sRAGE with variables of glucose metabolism and inflammatory markers.
Calprotectin sRAGE
r P r P
Calprotectin — — –0.35 0.013
sRAGE –0.35 0.013 — —
BMI 0.52 <0.001 –0.57 <0.001
BF 0.52 <0.001 –0.64 <0.001
Waist circumference 0.62 0.002 –0.75 <0.001
WHR 0.63 0.002 –0.72 <0.001
Glucose 0.30 0.090 –0.36 0.031
Insulin 0.38 0.030 –0.44 0.008
QUICKI –0.46 0.009 0.60 <0.001
Leptin 0.52 0.002 –0.40 0.019
Fibrinogen 0.40 0.029 –0.51 0.003
CRP 0.42 0.025 –0.73 <0.001
IL-6 0.29 0.063 –0.54 <0.001
TNF-α 0.22 0.173 –0.31 0.039
PAI-1 0.57 <0.001 –0.43 0.002
Adiponectin –0.27 0.252 0.49 0.022
Bold values are statistically significant P values.
VAT was observed in the common sam-
ples of both studies (n = 39).
An increased macrophage infiltration
in adipose tissue of obese patients (espe-
cially those with a high BMI) such as the
patients included in this study is a well-
established feature. To identify which
cell type preferentially contributed to the
observed calprotectin levels, adipocytes
and SVFCs were isolated from VAT sam-
ples obtained from 15 morbidly obese
patients and the expression of S100A8
and S100A9 was determined. Although
S100A8 and S100A9 expression was evi-
dent in the mature adipocytes, gene ex-
pression levels were mainly detected in
SVFCs (P < 0.001) (Figures 2C, D).
Calprotectin Gene Expression Levels
in VAT in Relation to Macrophages
Because macrophages represent a rele-
vant cell type source in proinflammatory
cytokine production and release and
both S100A8 and S100A9 were mainly
expressed in SVFCs, the macrophage-
specific marker CD68 was used to evalu-
ate the impact of resident macrophages
to the overall expression of S100A8 and
S100A9 in the SVFCs of adipose tissue.
As expected, the mRNA of CD68 was up-
regulated in VAT of obese NG individu-
als compared to LN volunteers (P =
0.010), being further increased in obese
T2D patients (P = 0.003) (Figure 3A). A
positive association between both
S100A8 (r = 0.62; P < 0.001) and S100A9
(r = 0.62; P < 0.001) with CD68 mRNA
levels was also detected (Table 3).
We also evaluated the gene expression
levels of CD11B, since a rapid increase of
this antigen in the surface of monocytes
after its stimulation with S100A8 or
S100A9 was observed. We showed that
mRNA expression levels of CD11B in
VAT were significantly upregulated (P =
0.030) in both obese NG and T2D patients
compared to LN volunteers (Figure 3B).
Furthermore, a significant positive associ-
ation between gene expression levels of
S100A8 (r = 0.56; P = 0.003) and S100A9
(r = 0.51; P = 0.006) with CD11B was ob-
served (Table 3). We analyzed the mRNA
levels of MCP1, a monocyte chemotactic
protein that plays an important role in
the recruitment of monocytes to adipose
tissue, finding a significant upregulation
(P = 0.004) in T2D obese patients com-
pared to LN volunteers, together with a
positive correlation with S100A8 and
S100A9 mRNA levels (Figure 3C, Table 3).
Given that the calprotectin subunits
are particularly susceptible to oxidative
modification, we next investigated the
role of NOX2, a catalytic subunit of the
macrophage NADPH oxidase (27), in
obesity and obesity-associated T2D as
well as the association with both S100A
subunits. The expression levels of NOX2
in VAT were significantly increased (P =
0.007) in T2D patients compared with LN
and obese NG volunteers (Figure 3D).
Moreover, a highly significant associa-
tion (P < 0.001) between gene expression
levels of NOX2 and both calprotectin
subunits (Table 3) was observed.
Circulating and mRNA Adipose
Calprotectin Levels Correlate with
Chronic Low-Grade Obesity-
Associated Inflammation: Role of
TNF-α in the Gene Expression Levels of
S100A in Human Adipocytes
Circulating concentrations of calpro-
tectin were positively correlated (P <
0.01) with the inflammatory and pro-
thrombotic markers leptin, CRP, PAI-1
and fibrinogen (Table 2). We also found
a significant negative correlation be-
tween sRAGE levels and leptin, CRP,
IL-6, PAI-1, fibrinogen and TNF-α con-
centrations as well as a positive associa-
tion with adiponectin levels (Table 2).
Analogously, S100A8 and S100A9 gene
expression levels in VAT were positively
associated (P < 0.01) with the inflamma-
tory markers IL-6, E-selectin and ICAM-1
(Table 3).
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Figure 2. Analysis of the calprotectin subunits S100A8 and S100A9 in VAT. (A, B) Gene ex-
pression levels of S100A8 and S100A9 in VAT of LN, obese NG and obese T2D volunteers.
Bars represent the mean ± SEM of the ratio between the gene expression to 18S rRNA. The
expression level in LN subjects was assumed to be 1 (LN: n = 9; NG: n = 10; T2D: n = 10).
Differences between groups were analyzed by one-way ANOVA followed by Tukey tests.
*P < 0.05, **P < 0.01, versus LN, and †P < 0.05 versus NG. (C, D) Comparison of S100A8 and
S100A9 gene expression in adipocytes and SVFCs isolated from VAT of obese patients.
Bars represent the mean ± SEM of the ratio between the gene expression to 18S rRNA. The
expression level in adipocytes was assumed to be 1 (adipocytes: n = 9; SVFCs: n = 11).
Statistical differences were assessed by two-tailed unpaired Student t tests. ***P < 0.001
versus adipocytes.
TNF-α is linked to the inflammatory
response in obesity, and it is known to
regulate the production of certain
adipokines. We found that gene expres-
sion levels of the inflammatory marker
TNFA in VAT were threefold higher in
obese individuals than in LN volun-
teers, being further upregulated (P <
0.01) in T2D obese patients (Figure 4A).
In addition, a positive correlation of the
TNFA gene expression with the mRNA
levels of S100A8 and S100A9 was also
found (P < 0.01) (Table 3). On the basis
of the positive correlation of the S100A8
and S100A9 transcripts with TNFA, to
establish a causative link between them,
the effect of TNF-α on S100A8 and
S100A9 expression in human adipocytes
was examined. Cells were stimulated
with increasing concentrations of
TNF-α for 24 h. As shown in Figures 4B
and C, TNF-α treatment significantly
enhanced the mRNA levels of S100A8
(P < 0.05). We also detected an in-
creased gene expression of S100A9, al-
though the differences were not statisti-
cally significant.
DISCUSSION
It is now broadly accepted that obe-
sity-associated low-grade chronic inflam-
mation leads to the development of both
insulin resistance and cardiovascular dis-
ease (28). In this sense, the S100 proteins
are reportedly involved in a large num-
ber of cellular functions such as inflam-
matory response, cell growth and differ-
entiation, cytoskeleton rearrangement,
immune response or energy metabolism
(17). The main findings in the present
study are as follows: (i) the increased lev-
els of calprotectin in obesity and obesity-
associated T2D, which decrease after
weight loss achieved by RYGB; (ii) the
reduced levels of sRAGE in obesity and
obesity-associated T2D as well as their
inverse correlation with calprotectin con-
centrations; (iii) the elevated gene ex-
pression levels of the calprotectin sub-
units S100A8 and S100A9 in obesity,
which are related to monocyte-
macrophage content in VAT; and (iv) the
correlation of both circulating and
mRNA adipose calprotectin levels with
chronic low-grade obesity-associated in-
flammation, establishing a causative link
with TNF-α.
Calprotectin has been recently de-
scribed as a novel marker of obesity (3).
In agreement with previous results
(3,29), we showed an increase of calpro-
tectin concentrations in both obesity and
obesity-associated T2D. These data to-
gether with the strong positive associa-
tion with anthropometric variables such
as BMI, BF, waist circumference and
WHR highlight the link between calpro-
tectin and obesity. It would be interesting
to evaluate the influence of hormonal or
sexual factors on the circulating levels of
calprotectin. However, at our institution,
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Figure 3. Gene expression levels of CD68 (A), CD11B (B), MCP1 (C) and NOX2 (D) in VAT of
LN, obese NG and obese T2D volunteers. Bars represent the mean ± SEM of the ratio be-
tween the gene expression to 18S rRNA. The expression level in LN subjects was assumed
to be 1 (LN: n = 9; NG: n = 10; T2D: n = 10). Differences between groups were analyzed by
one-way ANOVA followed by Tukey tests. *P < 0.05, **P < 0.01, versus LN, and †P < 0.05 ver-
sus NG.
Table 3. Univariate analysis of the correlations between mRNA expression levels of S100A8
and S100A9 in VAT with inflammatory markers.
S100A8 mRNA S100A9 mRNA
r P r P
S100A8 mRNA — — 0.60 <0.001
S100A9 mRNA 0.60 <0.001 — —
CD68 mRNA 0.62 <0.001 0.62 <0.001
CD11B mRNA 0.56 0.003 0.51 0.006
MCP1 mRNA 0.64 <0.001 0.63 <0.001
NOX2 mRNA 0.74 <0.001 0.88 <0.001
TNFA mRNA 0.61 <0.001 0.65 <0.001
Waist circumference 0.82 0.014 0.31 0.454
WHR 0.80 0.018 0.60 0.118
IL-6 0.51 0.017 0.63 0.002
E-selectin 0.53 0.024 0.56 0.013
ICAM-1 0.72 <0.001 0.74 <0.001
Bold values are statistically significant P values.
as well as in all obesity specialized cen-
ters, the majority of morbidly obese sub-
jects undergoing RYGB are females, and
the relative percentage of males sched-
uled for RYGB is low. To avoid the po-
tential additional confounding effect of
gender differences, we designed the
present study to assess the impact of cal-
protectin only in females undergoing
RYGB. In this regard, it is also worth-
while to mention that no significant asso-
ciation was found between calprotectin
levels and gender in a study including
139 subjects (30).
Our study further provides evidence
that both obese NG individuals and
obese T2D patients exhibit lower circu-
lating concentrations of sRAGE, a soluble
form of the putative receptor of calpro-
tectin. In this sense, it has been described
that obese subjects showed lower levels
of sRAGE than nonobese subjects (31),
but studies analyzing the relationship be-
tween obesity and sRAGE are scarce.
Our data suggest that low levels of
sRAGE may be another factor involved
in the low-grade chronic inflammation
associated with obesity. Recent studies
have shown that plasma levels of sRAGE
are downregulated in chronic hypergly-
cemia (32), with plasma sRAGE concen-
trations being decreased in patients with
essential hypertension (33). RAGE is an
important pathogenetic factor in the de-
velopment of long-term renal changes in
T2D (34), and the administration of
sRAGE has been suggested to exert a
protective effect against diabetic compli-
cations. In this sense, the progression of
atherosclerosis in diabetic mice is inhib-
ited by the competition of RAGE with its
soluble form (35). Of note, a negative
correlation of sRAGE with fasting glu-
cose and insulin as well as a positive as-
sociation with the QUICKI index was
found in the present study. In this re-
gard, the low sRAGE concentrations may
represent a risk factor for the develop-
ment or progression of diabetic compli-
cations. Indeed, sRAGE has been pro-
posed as an early and sensitive
biomarker for the occurrence of acceler-
ated atherosclerosis mediated by oxida-
tive stress in diabetes mellitus (36). These
findings contrast with those of Nin et al.
(37), reporting higher plasma sRAGE lev-
els in incident cardiovascular disease as
well as an association with all-cause
mortality in individuals with T1D. In this
regard, it has to be stressed that the pa-
tients included in our obese T2D group
do not have a long diabetes history (<2–3
years, as evidenced from their anamnesis
and biochemical determinations leading
to the current diagnosis). Undoubtedly,
the duration and progression of the dis-
ease, as well as the individual’s suscepti-
bility together with the metabolic control
achieved during the time course of the
disease, are likely to exert a relevant im-
pact on the circulating levels of sRAGE.
In this context, a long diabetic history
with poor diabetic control is likely to be
associated with an increase in both circu-
lating concentrations of the inflamma-
tory cytokines and chemokines. The re-
duced sRAGE levels in our group of T2D
patients with short duration of their dis-
ease suggests that sRAGE downregula-
tion is an early event in the history of di-
abetes and is more related to metabolic
control than to disease duration. In this
sense, the median follow-up duration
was 12.3 years in the study by Nin et al.
(37) and 9.1 years in the study by
Thomas et al. (38), establishing duration
of diabetes as one of the main indepen-
dent determinants of sRAGE concentra-
tions. The inverse correlation between
circulating levels of calprotectin and
sRAGE found in our study may be point-
ing to a plausible implication of calpro-
tectin in a negative-feedback mechanism
in the RAGE signaling pathway, which is
in line with previous results regarding
S100A12, another member of the S100
protein family (32). Bariatric surgery is
known to produce a marked weight loss
and an improvement of the inflamma-
tory state, specifically characterized by a
decrease in several inflammatory media-
tors and an increase in the antiinflamma-
tory marker adiponectin (39). Our results
show a reduction in calprotectin concen-
trations after weight loss achieved by
RYGB, indicating an association with
adipose tissue and weight loss, which is
in accordance with the study by Nijhuis
et al. (29), although the specific bariatric
surgery technique was not specified in
that study. Of note, we observed a posi-
tive correlation between differences in
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Figure 4. Effect of TNF-α on the expression
of both calprotectin subunits S100A8 and
S100A9 in human omental adipocytes.
Gene expression levels of TNFA (A) in VAT
of LN, obese NG and obese T2D volun-
teers. Bars represent the mean ± SEM of
the ratio between the gene expression to
18S rRNA. The expression level in LN sub-
jects was assumed to be 1 (LN: n = 9; NG:
n = 10; T2D: n = 10). Differences between
groups were analyzed by one-way
ANOVA followed by Tukey tests. **P < 0.01
versus LN. Bar graphs show the effect of
coincubation for 24 h of TNF-α with omen-
tal adipocytes on the transcript levels of
S100A8 (B) and S100A9 (C). The gene ex-
pression levels in unstimulated cells was as-
sumed to be 1. Values are the mean ±
SEM (n = 6 per group). Differences be-
tween groups were analyzed by one-way
ANOVA followed by Tukey tests. *P < 0.05
versus unstimulated cells.
the calprotectin levels and changes in the
WHR and concentrations of the inflam-
matory markers CRP and vWF in the pa-
tients undergoing RYGB. This result
highlights the role of calprotectin in rela-
tion to chronic low-grade obesity-
 associated inflammation.
Because adipose tissue–derived
adipokines play multiple roles in the
body and can be considered as a link be-
tween obesity and the molecular events
that lead to T2D development, we ana-
lyzed the gene expression levels of the
calprotectin subunits S100A8 and S100A9
in VAT. To our knowledge, this is the
first study describing elevated mRNA of
both calprotectin subunits in VAT in
human obesity-associated T2D. How-
ever, the lack of correlation between gene
expression levels and the circulating con-
centrations of calprotectin suggests that
in addition to VAT, a further source is
contributing to the increased plasma cal-
protectin levels in obesity-associated
T2D. In this sense, no evidence of dys-
regulation of mRNA levels of S100A8 in
obese or T2D patients in skeletal muscle
as well as no correlation with circulating
calprotectin levels have been described
(3). To gain more insight into the source
of production, we further analyzed the
gene expression levels of S100A8/A9 in
isolated adipocytes and SVFCs, finding a
higher expression in the SVFCs. More-
over, no differences in mRNA levels be-
tween obese NG volunteers and obese
patients with T2D were found in isolated
adipocytes, thereby suggesting a more
pronounced contribution of SVFC to the
overall expression of calprotectin sub-
units in VAT. Obesity-associated inflam-
mation is characterized by an infiltration
of macrophages in adipose tissue, which
is likely a direct response to the abnor-
mal fat metabolism caused by the in-
creased adiposity. Because mRNA levels
of S100A8/A9 and CD68 were positively
correlated, S100A8/A9 expression levels
may reflect the degree of VAT
macrophage infiltration. It has been
shown that calprotectin may participate
in inflammation by enhancing CD11B ex-
pression in human monocytes and by
participating in the transendothelial mi-
gration mechanism (40). Thus, calpro-
tectin substantially contributes to the re-
cruitment of monocytes to an
inflammatory site. In this sense, it has
been shown that circulating monocytes
of T1D patients display increased CD11B
and CD18 surface expression (2). Inter-
estingly, we found an upregulation of
CD11B in VAT of obese patients with
T2D compared with LN volunteers.
Moreover, a positive association between
the gene expression levels of S100A8 and
S100A9 with CD11B was also found.
Taken together, these findings suggest
that the presence of S100A8/A9 in in-
flamed VAT may be favoring the
macrophage-monocyte migration and re-
cruitment to inflammatory sites con-
tributing to the obesity-associated low-
grade chronic inflammation. It has been
described that an increase in MCP1 ex-
pression in adipose tissue contributes to
macrophage infiltration into this tissue
and insulin resistance development (41).
In this regard, an association of both
 calprotectin subunits with circulating
MCP-1 was detected in our study. It has
been proposed that the inactivation of
the chemotactic activity of S100A8 by
hypochlorite oxidation may provide a
mechanism for limiting excess accumula-
tion of leukocytes and terminating the
progression of acute inflammation (42).
In this sense, a putative role for calpro-
tectin as a chemotactic factor might be
put forward.
A hallmark of S100/calgranulin
polypeptides is their association with
chronic inflammation, such as human in-
flammatory bowel diseases (43). A posi-
tive association of calprotectin with CRP,
IL-6, PAI-1 and TNF-α, well-established
markers of chronic inflammation, was
observed in the present study. Moreover,
gene expression levels were positively
correlated with IL-6, E-selectin and
ICAM-1. Our findings in relation to in-
flammation are in line with previous re-
ports where IL-6 infusion was found to
induce mRNA expression of both S100A8
and S100A9 in skeletal muscle tissue (44).
Calprotectin was also found to be associ-
ated with CRP (45,46) as well as with
other acute-phase proteins such as fib-
rinogen and α1-antitrypsin (45,47). In-
creased oxidative stress in adipocytes
causes dysregulated expression of
adipokines, representing one of the
causes of inflammatory changes in adi-
pose tissue (48). Because S100A8 and
S100A9 were proposed as regulators of
the macrophage subunit NOX2 of the
NADPH oxidase (49), we analyzed
mRNA NOX2 levels in VAT, finding an
upregulation in obese patients with T2D
compared to LN and obese NG volun-
teers. In addition, a positive correlation
of NOX2 with both calprotectin subunits
was found. These findings further sug-
gest a role for calprotectin in VAT inflam-
mation through NOX2, increasing the
generation of radical oxygen species.
A positive correlation between the
mRNA levels of both S100A subunits
with that of TNFA in VAT was also ob-
served. In addition, our in vitro studies
showed an induction of the S100A8 ex-
pression levels in human adipocyte cul-
ture upon stimulation with the cytokine
TNF-α. In mice, TNF-α (14) and IL-1 (13)
induced S100A8 and S100A9 expression
in endothelial cells and macrophages.
Taken together, these findings point to
calprotectin’s implication in the develop-
ment of insulin resistance via either direct
or indirect effects on inflammation. In ad-
dition to its function as an inflammatory
factor, murine S100A8 may also have an-
tiinflammatory activity, depending on its
extracellular concentration and circum-
stance of release (42). Most biological
functions relevant to inflammation re-
quire the release of calprotectin into the
extracellular space and the interaction
with one or several signaling compo-
nents. Although calprotectin interacts
with RAGE, the role of this interaction is
not clearly understood. In rheumatoid
arthritis, calprotectin was shown to inter-
act with RAGE, amplifying the proin-
flammatory cytokine production by
macrophages via the activation of nuclear
factor (NF)-κB and p38 mitogen-activated
protein kinase (MAPK) (50). RAGE levels
have been found to be decreased in
R E S E A R C H  A R T I C L E
M O L  M E D  1 7 ( 1 1 - 1 2 ) 1 1 5 7 - 1 1 6 7 ,  N O V E M B E R - D E C E M B E R  2 0 1 1  |  C A T A L Á N E T  A L .  |  1 1 6 5
chronic inflammatory diseases including
atherosclerosis, diabetes, renal failure and
aging. Regarding inflammation, a nega-
tive correlation between sRAGE and CRP,
IL-6, PAI-1 and TNF-α together with a
positive association with adiponectin was
shown in the present study. Interestingly,
serum sRAGE levels in rheumatoid
arthritis patients were negatively associ-
ated with serum levels of CRP (51). It was
also recently described that increased
serum CRP together with reduced con-
centrations of sRAGE appear to be due to
elevated TNF-α levels (52). In Il10 null
mice, a murine model of colitis, no in-
flammation in rectosigmoid colon and a
decrease in circulating concentrations of
TNF-α were observed after treatment
with sRAGE (53). Thus, the association of
plasma sRAGE with components of in-
flammatory pathways highlights the role
of the soluble form of the receptor in
modulation of inflammation, probably
acting as a decoy and competing with
RAGE for its ligands. In this sense, anti-
RAGE strategies including sRAGE-like
molecules were proposed in relation to
inflammation (54).
The increased levels of calprotectin in
obesity and obesity-associated T2D to-
gether with its positive association with
inflammatory markers as well as the
higher expression levels in the stro-
movascular fraction in VAT suggests a
role for this protein as a chemotactic fac-
tor in the recruitment of macrophages to
VAT, increasing inflammation and the
development of obesity-associated
 comorbidities.
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